Cargando…

Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy

Despite the wide use of immune checkpoint inhibition for the treatment of melanoma, the mechanisms leading to long-term stable disease are incompletely understood. Patients with metastatic melanoma who had received ipilimumab alone or ipilimumab plus nivolumab 2+years prior and attained at least 6 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchbinder, Elizabeth I., Pfaff, Kathleen L., Turner, Madison M., Manos, Michael, Ouyang, Olivia, Ott, Patrick A., Giobbie-Hurder, Anita, Rodig, Scott J., Hodi, F. Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168111/
https://www.ncbi.nlm.nih.gov/pubmed/37115942
http://dx.doi.org/10.1097/CJI.0000000000000470
_version_ 1785038804752531456
author Buchbinder, Elizabeth I.
Pfaff, Kathleen L.
Turner, Madison M.
Manos, Michael
Ouyang, Olivia
Ott, Patrick A.
Giobbie-Hurder, Anita
Rodig, Scott J.
Hodi, F. Stephen
author_facet Buchbinder, Elizabeth I.
Pfaff, Kathleen L.
Turner, Madison M.
Manos, Michael
Ouyang, Olivia
Ott, Patrick A.
Giobbie-Hurder, Anita
Rodig, Scott J.
Hodi, F. Stephen
author_sort Buchbinder, Elizabeth I.
collection PubMed
description Despite the wide use of immune checkpoint inhibition for the treatment of melanoma, the mechanisms leading to long-term stable disease are incompletely understood. Patients with metastatic melanoma who had received ipilimumab alone or ipilimumab plus nivolumab 2+years prior and attained at least 6 months of stable disease were identified. Positron emission tomography/computed tomography (PET/CT) was performed. Pretreatment and posttreatment biopsies of areas of stable disease were assessed for tumor, fibrosis, and inflammation. Seven patients underwent PET/CT and tissue biopsy. Fluorodeoxyglucose avid lesions on PET/CT ranged from no activity to an SUV of 22. In 6 patients, the residual stable lesions were composed of necrosis and fibrosis with a prominent pigment containing macrophages and no residual melanoma. In 1 patient, a nodal lesion demonstrated melanoma with active inflammation. In most patients with durable stable disease after treatment with ipilimumab or ipilimumab/nivolumab, residual lesions demonstrated predominantly necrosis and fibrosis consistent with resolving lesions. The presence of melanophages in these samples may suggest ongoing immune surveillance. One patient did demonstrate residual melanoma, indicating the need for ongoing monitoring of this patient population.
format Online
Article
Text
id pubmed-10168111
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-101681112023-05-10 Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy Buchbinder, Elizabeth I. Pfaff, Kathleen L. Turner, Madison M. Manos, Michael Ouyang, Olivia Ott, Patrick A. Giobbie-Hurder, Anita Rodig, Scott J. Hodi, F. Stephen J Immunother Clinical Studies Despite the wide use of immune checkpoint inhibition for the treatment of melanoma, the mechanisms leading to long-term stable disease are incompletely understood. Patients with metastatic melanoma who had received ipilimumab alone or ipilimumab plus nivolumab 2+years prior and attained at least 6 months of stable disease were identified. Positron emission tomography/computed tomography (PET/CT) was performed. Pretreatment and posttreatment biopsies of areas of stable disease were assessed for tumor, fibrosis, and inflammation. Seven patients underwent PET/CT and tissue biopsy. Fluorodeoxyglucose avid lesions on PET/CT ranged from no activity to an SUV of 22. In 6 patients, the residual stable lesions were composed of necrosis and fibrosis with a prominent pigment containing macrophages and no residual melanoma. In 1 patient, a nodal lesion demonstrated melanoma with active inflammation. In most patients with durable stable disease after treatment with ipilimumab or ipilimumab/nivolumab, residual lesions demonstrated predominantly necrosis and fibrosis consistent with resolving lesions. The presence of melanophages in these samples may suggest ongoing immune surveillance. One patient did demonstrate residual melanoma, indicating the need for ongoing monitoring of this patient population. Lippincott Williams & Wilkins 2023-06 2023-05-01 /pmc/articles/PMC10168111/ /pubmed/37115942 http://dx.doi.org/10.1097/CJI.0000000000000470 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Clinical Studies
Buchbinder, Elizabeth I.
Pfaff, Kathleen L.
Turner, Madison M.
Manos, Michael
Ouyang, Olivia
Ott, Patrick A.
Giobbie-Hurder, Anita
Rodig, Scott J.
Hodi, F. Stephen
Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
title Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
title_full Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
title_fullStr Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
title_full_unstemmed Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
title_short Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
title_sort brief communication on pathologic assessment of persistent stable metastatic lesions in patients treated with anti-ctla-4 or anti-ctla-4 + anti-pd-1 therapy
topic Clinical Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168111/
https://www.ncbi.nlm.nih.gov/pubmed/37115942
http://dx.doi.org/10.1097/CJI.0000000000000470
work_keys_str_mv AT buchbinderelizabethi briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy
AT pfaffkathleenl briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy
AT turnermadisonm briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy
AT manosmichael briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy
AT ouyangolivia briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy
AT ottpatricka briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy
AT giobbiehurderanita briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy
AT rodigscottj briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy
AT hodifstephen briefcommunicationonpathologicassessmentofpersistentstablemetastaticlesionsinpatientstreatedwithantictla4orantictla4antipd1therapy